HS-301

The primary objectives of Phase I are to observe the safety and tolerability of HS301 in the treatment of patients with locally advanced or metastatic solid tumors; to evaluate the DLT and MTD of HS301 in the treatment of patients with locally advanced or metastatic solid tumors. Secondary objectives are to evaluate the pharmacokinetic characteristics of HS301 in the treatment of patients with locally advanced or metastatic solid tumors; to evaluate the preliminary efficacy of HS301 in the treatment of patients with locally advanced or metastatic solid tumors. The primary objectives of Phase II are to further observe the efficacy of HS301 in the treatment of locally advanced or metastatic solid tumors with positive NTRK, ROS1, or ALK gene mutations. Secondary objectives are to observe the safety of HS301 in the treatment of locally advanced or metastatic solid tumors with positive NTRK, ROS1, or ALK gene mutations.